% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/next_TITE_QuasiBOIN.R
\name{next_TITE_QuasiBOIN}
\alias{next_TITE_QuasiBOIN}
\title{next_TITE_QuasiBOIN}
\usage{
next_TITE_QuasiBOIN(
  target,
  n,
  npend,
  y,
  ft,
  d,
  maxt = 28,
  p.saf = 0.6 * target,
  p.tox = 1.4 * target,
  elimination = NA,
  cutoff.eli = 0.95,
  extrasafe = FALSE,
  offset = 0.05,
  n.earlystop = 100,
  maxpen = 0.5,
  Neli = 3,
  print_d = FALSE,
  gdesign = FALSE
)
}
\arguments{
\item{target}{The target toxicity probability (example: \code{target <- 0.30}) or the target normalized equivalent 
toxicity score (ETS) (example: \code{target <- 0.47 / 1.5}).}

\item{n}{Number of patients treated at each dose level.}

\item{npend}{For Time-to-event Bayesian optimal interval (TITEBOIN)/Time-to-event generalized Bayesian optimal interval (TITEgBOIN), 
the number of pending patients at each dose level.For Bayesian optimal interval (BOIN)/Generalized Bayesian optimal interval (gBOIN), 
"NA" should be assigned.}

\item{y}{Number of patients with dose limiting toxicity (DLT) or the sum of Normalized equivalent toxicity score (ETS).}

\item{ft}{For Time-to-event Bayesian optimal interval (TITEBOIN)/Time-to-event generalized Bayesian optimal interval (TITEgBOIN), 
Total follow-up time for pending patients for toxicity at each dose level (days). For Bayesian optimal interval (BOIN)/
Generalized Bayesian optimal interval (gBOIN), "NA" should be assigned.}

\item{d}{Current dose level.}

\item{maxt}{For Time-to-event Bayesian optimal interval (TITEBOIN)/Time-to-event generalized Bayesian optimal interval (TITEgBOIN),
length of assessment window for toxicity (days). For Bayesian optimal interval (BOIN)/Generalized Bayesian optimal interval (gBOIN), 
"NA" should be assigned.}

\item{p.saf}{The lower bound. The default value is \code{p.saf=0.6*target}.}

\item{p.tox}{The upper bound. The default value is \code{p.tox=1.4*target}.}

\item{elimination}{Elimination of each dose (0,1 should be assigned, 0 means the dose is not eliminated,
1 means the dose is eliminated due to over toxic(\code{elimination=NA}, 0 is defaulted for each dose level)).}

\item{cutoff.eli}{The cutoff to eliminate an overly toxic dose for safety.
We recommend the default value of (\code{cutoff.eli=0.95}) for general use.}

\item{extrasafe}{Set \code{extrasafe=TRUE} to impose a more stringent stopping rule}

\item{offset}{A small positive number (between 0 and 0.5) to control how strict the
stopping rule is when \code{extrasafe=TRUE}. A larger value leads to a more
strict stopping rule. The default value \code{offset=0.05} generally works well.}

\item{n.earlystop}{The early stopping parameter. The default value is \code{n.earlystop=100}.}

\item{maxpen}{For Time-to-event Bayesian optimal interval (TITEBOIN)/Time-to-event generalized Bayesian optimal interval 
(TITEgBOIN), the upper limit of the ratio of pending patients. For Bayesian optimal interval (BOIN)/Generalized Bayesian optimal
interval (gBOIN), "NA" should be assigned.}

\item{Neli}{The sample size cutoff for elimination. The default is \code{Neli=3}.}

\item{print_d}{Print the additional result or not. The default value is \code{print_d=FALSE}.}

\item{gdesign}{For Bayesian optimal interval (BOIN) and Time-to-event bayesian optimal interval (TITEBOIN), "FALSE" should be 
assigned. For Generalized Bayesian optimal interval (gBOIN) and Time-to-event generalized bayesian optimal interval (TITEgBOIN), 
"TRUE" should be assigned . The default is \code{gdesign=FALSE}.}
}
\value{
\code{next_TITE_QuasiBOIN()} returns the toxicity probability and the recommended dose level for the next cohort
including: (1) the lower Bayesian optimal boundary (\code{lambda_e})
(2) the upper Bayesian optimal boundary (\code{lambda_d})
(3) The number of patients or the effective sampe size (ESS) at each dose level (\code{ESS})
(4) The dose limiting toxicity (DLT) rate or mu (the estimated quasi-Bernoulli toxicity probability) at each dose level (\code{mu})
(5) the recommended dose level for the next cohort as a numeric value under (\code{d})
}
\description{
Determine the dose for the next cohort of new patients for single-agent trials using Bayesian optimal interval (BOIN)/
Generalized Bayesian optimal interval (gBOIN)/Time-to-event bayesian optimal interval (TITEBOIN)/Time-to-event generalized 
Bayesian optimal interval (TITEgBOIN) designs.
}
\examples{
#For Bayesian optimal interval (BOIN) design
target<-0.3
next_TITE_QuasiBOIN(target=target,n=c(3,3,4,4,4,0),npend=NA, y=c(0,0,1,1,1,0), ft=NA,
                    d=5, maxt=NA,p.saf= 0.6 * target, p.tox = 1.4 * target,elimination=NA,
                    cutoff.eli = 0.95,extrasafe = FALSE, n.earlystop = 10,
                    maxpen=NA,print_d = TRUE,gdesign=FALSE)


#For Generalized Bayesian optimal interval (gBOIN) design
target=0.47/1.5
next_TITE_QuasiBOIN(target=target,n=c(3,3,4,4,4,0),npend=NA,
                    y=c(0, 0, 0.5/1.5, 1.0/1.5, 1.5/1.5, 0),ft=NA, d=5, maxt=NA,
                    p.saf= 0.6 * target, p.tox = 1.4 * target,elimination=NA,
                    cutoff.eli = 0.95,extrasafe = FALSE, n.earlystop = 10,
                    maxpen=NA,print_d = TRUE,gdesign=TRUE)


#For Time-to-event bayesian optimal interval (TITEBOIN) design
target=0.3
next_TITE_QuasiBOIN(target=target,n=c(3,3,4,4,4,0),npend=c(0,0,0,1,2,0), y=c(0,0,1,1,1,0),
                   ft=c(0, 0, 0, 14, 28, 0),d=5, maxt=28,p.saf= 0.6 * target,
                    p.tox = 1.4 * target,elimination=NA,cutoff.eli = 0.95,
                    extrasafe = FALSE, n.earlystop = 10,maxpen=0.5,print_d = TRUE,
                    gdesign=FALSE)


#For Time-to-event generalized bayesian optimal interval (TITEgBOIN) design
target=0.47/1.5
next_TITE_QuasiBOIN(target=target,n=c(3,3,4,4,4,0),npend=c(0,0,0,1,2,0),
                    y=c(0, 0, 0.5/1.5, 1.0/1.5, 1.5/1.5, 0),ft=c(0, 0, 0, 14, 28, 0),
                    d=5, maxt=28,p.saf= 0.6 * target, p.tox = 1.4 * target,
                    elimination=NA,cutoff.eli = 0.95,extrasafe = FALSE,
                    n.earlystop = 10,maxpen=0.5,print_d = TRUE,gdesign=TRUE)
}
\references{
1. Liu S. and Yuan, Y. (2015). Bayesian optimal interval designs for phase I clinical trials, Journal of the Royal Statistical Society: Series C , 64, 507-523.
2. Yuan, Y., Hess, K. R., Hilsenbeck, S. G., & Gilbert, M. R. (2016). Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clinical Cancer Research, 22(17), 4291-4301.
3. Zhou, H., Yuan, Y., & Nie, L. (2018). Accuracy, safety, and reliability of novel phase I trial designs. Clinical Cancer Research, 24(18), 4357-4364.
4. Zhou, Y., Lin, R., Kuo, Y. W., Lee, J. J., & Yuan, Y. (2021). BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clinical Cancer Informatics, 5, 91-101.
5. Takeda K, Xia Q, Liu S, Rong A. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades. Pharm Stat. 2022 Mar;21(2):496-506. doi: 10.1002/pst.2182. Epub 2021 Dec 3. PMID: 34862715.
6. Yuan, Y., Lin, R., Li, D., Nie, L. and Warren, K.E. (2018). Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research, 24(20): 4921-4930.
7. Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, Jun Yin, gBOIN: A Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points, Journal of the Royal Statistical Society Series C: Applied Statistics, Volume 68, Issue 2, February 2019, Pages 289â€“308, https://doi.org/10.1111/rssc.12263.
8. Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. 2020 Oct 1;21(4):807-824. doi: 10.1093/biostatistics/kxz007. PMID: 30984972; PMCID: PMC8559898.
9. Hsu C, Pan H, Mu R (2022). _UnifiedDoseFinding: Dose-Finding Methods for Non-Binary Outcomes_. R package version 0.1.9, <https://CRAN.R-project.org/package=UnifiedDoseFinding>.
}
